Fritillaria thunbergii Miq. Extract ameliorated experimental pulmonary fibrosis partly through the PI3K/AKT/FOXO signalling pathway
Journal of Ethnopharmacology · 2025
DOI: 10.1016/j.jep.2025.119445 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Ethnopharmacology, 2025. Verfasst von Siwen Feng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Hospital, Beijing University of Chinese Medicine, Shenzhen, 518172, China. Electronic address: 20230941539@bucm.edu.cn. Hauptthemen laut MEDLINE: Pulmonary Fibrosis, Proto-Oncogene Proteins c-akt, Fritillaria, Plant Extracts. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
ETHNOPHARMACOLOGICAL RELEVANCE: Pulmonary fibrosis is an irreversible lung disease with a high mortality rate. Zhebeimu (ZBM, Fritillaria thunbergii Miq.) is a Chinese medicine commonly used for the treatment of pulmonary fibrosis in China. AIM OF THE STUDY: In this study, the protective effect and mechanism of ZBM extract in the treatment of pulmonary fibrosis were investigated in vivo and in vitro. MATERIALS AND METHODS: The protective effect of ZBM extract was assessed using an in vivo model of bleomycin (BLM) tracheal drip and transforming growth factor-β(TGF-β1)-induced fibroblasts to simulate pulmonary fibrosis, and lung function, lung histopathological status and hydroxyproline were tested. Relevant pathways were detected using protein blotting, immunofluorescence and immunohistochemistry. RESULTS: ZBM extract effectively improved lung function, inflammatory changes and fibrotic deposition in the lungs, and reduced the expression of fibroblast markers in mice. In addition, ZBM extract significantly inhibited TGF-β1-induced hyperphosphorylation of FOXO3, and simultaneously improved the low expression level of FOXO3 prototype protein and significantly reduced the phosphorylation level of PI3K-p85 and AKT1, suggesting that ZBM extract improves lung fibrosis by inhibiting the over-activation of PI3K/AKT/FOXO signalling pathway. CONCLUSION: The PI3K/AKT/FOXO signalling pathway is critical for ZBM extract to improve pulmonary fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shenzhen Hospital, Beijing University of Chinese Medicine, Shenzhen, 518172, China. Electronic address: 20230941539@bucm.edu.cn.
- School of Life Sciences, Beijing University of Chinese Medicine, Beijing, 100029, China. Electronic address: 460986109@qq.com.
- Shenzhen Research Institute, Beijing University of Chinese Medicine, Shenzhen, 518118, China. Electronic address: dingqisc@163.com.
- Shenzhen Hospital, Beijing University of Chinese Medicine, Shenzhen, 518172, China. Electronic address: yshi@bucm.edu.cn.
Zitieren
APA
Feng, S., Xu, G., Ding, Q., & Shi, Y. (2025). Fritillaria thunbergii Miq. Extract ameliorated experimental pulmonary fibrosis partly through the PI3K/AKT/FOXO signalling pathway. Journal of Ethnopharmacology. https://doi.org/10.1016/j.jep.2025.119445
Vancouver
Feng S, Xu G, Ding Q, Shi Y. Fritillaria thunbergii Miq. Extract ameliorated experimental pulmonary fibrosis partly through the PI3K/AKT/FOXO signalling pathway. Journal of Ethnopharmacology. 2025. doi:10.1016/j.jep.2025.119445
BibTeX
@article{Feng2025,
author = {Feng, Siwen and Xu, Gonghao and Ding, Qi and Shi, Yuanyuan},
title = {Fritillaria thunbergii Miq. Extract ameliorated experimental pulmonary fibrosis partly through the PI3K/AKT/FOXO signalling pathway},
journal = {Journal of Ethnopharmacology},
year = {2025},
doi = {10.1016/j.jep.2025.119445}
}
EUVIMED